These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 2288439)

  • 1. Lipoprotein heterogeneity and its effect on apolipoprotein assays.
    Fruchart JC
    Scand J Clin Lab Invest Suppl; 1990; 198():51-7. PubMed ID: 2111936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of blood profile of atherogenic lipids using immunologic techniques].
    Fruchart JC; Bard JM; Clavey V; Fievet C
    Klin Wochenschr; 1990; 68 Suppl 22():43-5. PubMed ID: 2087078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Receptors and molecular heterogeneity of lipoprotein particles containing apolipoprotein A-I].
    Broutin H; Puchois P; Ailhaud G; Barbaras R; Torpier G; Fruchart JC
    Ann Biol Clin (Paris); 1988; 46(1):16-23. PubMed ID: 2839056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of high density lipoprotein particles.
    Fruchart JC; Ailhaud G; Bard JM
    Circulation; 1993 Apr; 87(4 Suppl):III22-7. PubMed ID: 8462177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different APO A-I containing lipoprotein particles on reverse cholesterol transport in fat cells.
    Barkia A; Barbaras R; Ghalim N; Puchois P; Ailhaud G; Fruchart JC
    Horm Metab Res Suppl; 1988; 19():10-2. PubMed ID: 3148546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles.
    Ziegler O; Méjean L; Igau B; Fruchart JC; Drouin P; Fiévet C
    Diabetes Metab; 1996 Jun; 22(3):179-84. PubMed ID: 8697305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.
    Rader DJ; Cain W; Ikewaki K; Talley G; Zech LA; Usher D; Brewer HB
    J Clin Invest; 1994 Jun; 93(6):2758-63. PubMed ID: 8201014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries].
    Bukowska H
    Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein abnormalities in chronic haemodialysis patients.
    Parsy D; Dracon M; Cachera C; Parra HJ; Vanhoutte G; Tacquet A; Fruchart JC
    Nephrol Dial Transplant; 1988; 3(1):51-6. PubMed ID: 3132640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipoprotein particles LpA-I, LpA-I: A-II and LpB in coronary artery disease].
    Calvo C; Olmos A; Ulloa N; Bustos A; Toledo L; Durán D; Naveas R
    Rev Med Chil; 2000 Jan; 128(1):9-16. PubMed ID: 10883517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipoprotein Lp(a) and CETP (cholesterol ester transfer protein): contribution of transgenic mice].
    Chapman J; Guérin M
    Bull Acad Natl Med; 1994 Mar; 178(3):427-34; discussion 434-6. PubMed ID: 8076182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a new precipitation procedure for estimating high density lipoprotein cholesterol: precipitation of apolipoprotein B associated cholesterol with concanavalin A.
    Pascal M; Wülfert E
    Ann Biol Clin (Paris); 1981; 39(6):343-50. PubMed ID: 7325424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of lipoprotein (a) and high density lipoproteins in transgenic mice.
    Rubin EM
    Atherosclerosis; 1994 Oct; 110 Suppl():S77-81. PubMed ID: 7857389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Apo(a) gene: structure/function relationships and the possible link with thrombotic atheromatous disease.
    Rees A; Bishop A; Morgan R
    Br Med Bull; 1990 Oct; 46(4):873-90. PubMed ID: 2151625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Change in the properties of model membranes interacting with atherogenic and "antiatherogenic" classes of lipoproteins with varying physicochemical characteristics].
    Gerasimova EN; Perova NV; Pasechnik VI; Ruuge EK; Tverdislov VA
    Kardiologiia; 1980 Aug; 20(8):12-5. PubMed ID: 7412087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipoprotein A].
    Verny C; Faucher C
    Ann Med Interne (Paris); 1992; 143(3):184-90. PubMed ID: 1524352
    [No Abstract]   [Full Text] [Related]  

  • 19. [What do we know about lipoproteins containing apo A-I?].
    Barkia A
    Ann Biol Clin (Paris); 1990; 48(8):529-35. PubMed ID: 2288439
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.